Qiagen Inks Molecular Diagnostics Partnership with Seegene - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 1:20PM CDT
Qiagen N.V. (QGEN) recently inked a worldwide collaboration agreement with multiplex molecular technologies and multiplex clinical molecular diagnostics developer Seegene Inc.
ACHN: 8.68 (+0.14), AMAG: 71.72 (+2.23), QGEN: 25.73 (+1.00)
Cataract - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d86sd5/cataract) has announced the addition of the "Cataract - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - CalAsia Pharmaceuticals, Inc. - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Laila Pharmaceuticals Pvt. Ltd. - Omeros Corporation - R-Tech Ueno, Ltd. For more information visit http://www.researchandmarkets.com/research/d86sd5/cataract
OMER: 17.33 (+0.29)
INSITE VISION INCORPORATED SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Wed Jun 17, 10:19AM CDT
Rigrodsky & Long, P.A.:
QLTI: 4.19 (+0.06)